
欧洲急性胰腺炎市场预测至 2030 年 – 区域分析 – 按产品(药物、诊断等)、病因(胆结石、酗酒、遗传性疾病、感染等)和最终用户(医院、诊断实验室、门诊手术中心等)
No. of Pages: 113 | Report Code: BMIRE00029223 | Category: Life Sciences
No. of Pages: 113 | Report Code: BMIRE00029223 | Category: Life Sciences
胰腺产生胰岛素,这是一种调节血糖水平的激素。胰腺炎会损害胰腺产生胰岛素的细胞,从而导致急性胰腺炎患者患糖尿病。患有急性胰腺炎的人患糖尿病的风险是普通人群的两倍。急性胰腺炎的各种严重程度都会出现糖尿病后遗症,并且可能伴随其他临床并发症。
根据 2022 年发表的《欧洲医学和药理学科学评论》,胰源性糖尿病的患病率为 5–10在西方糖尿病人群中,慢性胰腺炎占20%,急性胰腺炎占80%。根据 2021 年国家医学图书馆发表的一篇文章,约 23% 的急性胰腺炎患者可能在出院三年内患上糖尿病。此外,2020 年《胃肠病学杂志》上发表的一篇文章指出,急性胰腺炎后,约 3%、7%、9% 和 11% 的患者在出院 6、12、18 和 24 个月时分别发展为糖尿病。根据 MDPI 发表的一篇文章,到 2023 年,约 40% 的急性胰腺炎患者受到糖尿病前期和糖尿病的影响,死亡和再入院的风险比 2 型糖尿病患者更高。此外,大约 60.2% 的成人患者在急性胰腺炎后发展为糖尿病,9% 的儿童在急性复发性胰腺炎或慢性胰腺炎后发展为糖尿病,而且这种风险随着年龄的增长而增加。研究人员在一项比较重症和轻度急性胰腺炎的荟萃分析中发现,重症急性胰腺炎后糖尿病的发病率(约 39%)高于轻度急性胰腺炎(14%)。因此,急性胰腺炎患者或康复患者中糖尿病发病率的增加有助于欧洲急性胰腺炎市场的增长。
欧洲急性胰腺炎市场的产品、原因、最终用户
根据产品,欧洲急性胰腺炎市场分为药物、诊断等。 2022年诊断细分市场占据最大市场份额。
根据方法,欧洲急性胰腺炎市场分为胆结石、酗酒、遗传性疾病、感染等。 2022年,胆结石细分市场占据最大的市场份额。
根据最终用户,欧洲急性胰腺炎市场分为医院、诊断实验室、门诊手术中心等。 2022 年,医院细分市场占据最大的市场份额。
根据国家/地区,欧洲急性胰腺炎市场分为英国、德国、法国、意大利、西班牙、北欧国家、荷兰和欧洲其他地区。 2022 年,德国在欧洲急性胰腺炎市场份额中占据主导地位。
雅培 (Abbott Laboratories)、Actim Oy、百特国际公司 (Baxter International Inc)、波士顿科学公司 (Boston Scientific Corp)、Dynavax Technologies Corp、Fresenius Kabi AG、GE HealthCare Technologies Inc、Koninklijke Philips NV、美敦力 (Medtronic) Plc 和三星医疗保健是欧洲急性胰腺炎市场上的一些领先公司。
Strategic insights for Europe Acute Pancreatitis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 1,492.10 Million |
Market Size by 2030 | US$ 2,260.69 Million |
Global CAGR (2022 - 2030) | 5.3% |
Historical Data | 2020-2021 |
Forecast period | 2023-2030 |
Segments Covered |
By 供品
|
Regions and Countries Covered | 欧洲
|
Market leaders and key company profiles |
The regional scope of Europe Acute Pancreatitis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Acute Pancreatitis Market is valued at US$ 1,492.10 Million in 2022, it is projected to reach US$ 2,260.69 Million by 2030.
As per our report Europe Acute Pancreatitis Market, the market size is valued at US$ 1,492.10 Million in 2022, projecting it to reach US$ 2,260.69 Million by 2030. This translates to a CAGR of approximately 5.3% during the forecast period.
The Europe Acute Pancreatitis Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Acute Pancreatitis Market report:
The Europe Acute Pancreatitis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Acute Pancreatitis Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Acute Pancreatitis Market value chain can benefit from the information contained in a comprehensive market report.